Dimensional Fund Advisors LP Decreases Position in Enovis Co. (NYSE:ENOV)

Dimensional Fund Advisors LP lessened its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 2.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,899,446 shares of the company's stock after selling 87,112 shares during the quarter. Dimensional Fund Advisors LP owned approximately 5.10% of Enovis worth $127,226,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Aster Capital Management DIFC Ltd purchased a new stake in shares of Enovis in the fourth quarter valued at $29,000. Quadrant Capital Group LLC raised its stake in Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after purchasing an additional 239 shares during the last quarter. UMB Bank n.a. lifted its holdings in Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after purchasing an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after purchasing an additional 300 shares during the last quarter. Finally, Sterling Capital Management LLC raised its position in shares of Enovis by 56.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock valued at $143,000 after buying an additional 1,173 shares during the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Trading Up 2.1 %

Enovis stock traded up $0.74 during trading on Friday, reaching $35.34. The company had a trading volume of 196,639 shares, compared to its average volume of 985,158. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -16.13 and a beta of 1.86. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $53.84. The stock's 50 day moving average price is $35.79 and its two-hundred day moving average price is $41.82.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. As a group, equities analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.